➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Mallinckrodt
Johnson and Johnson
Boehringer Ingelheim
Moodys

Last Updated: April 12, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SERTRALINE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Sertraline Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000321 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed Friends Research Institute, Inc. Phase 4 1996-10-01 The purpose of this study is to evaluate the efficacy of desipramine, sertraline, and placebo on methamphetamine dependent gay men with AIDS.
NCT00000321 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed National Institute on Drug Abuse (NIDA) Phase 4 1996-10-01 The purpose of this study is to evaluate the efficacy of desipramine, sertraline, and placebo on methamphetamine dependent gay men with AIDS.
NCT00000378 Antidepressant Treatment of Melancholia in Late Life Completed National Institute of Mental Health (NIMH) Phase 4 1997-07-01 The purpose of this study is to compare the safety and effectiveness of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who have major depression. SSRIs are effective in the treatment of major depression. However, there is also evidence that SSRIs may be significantly less effective than TCAs for patients with late-life major depression with melancholia. Since SSRIs seem to be easier to take than TCAs and are more widely prescribed, it is important to determine which of these types of antidepressants works best to treat these patients. Patients will be assigned randomly to receive either sertraline (a SSRI) or nortriptyline (a TCA) for 12 weeks. Patients will be monitored for symptoms, side effects, and quality of life. If a patient responds to treatment, he/she will participate in a 6-month continuation phase in which he/she will continue to receive the same medication. An individual may be eligible for this study if he/she: Has unipolar major depression (with some exceptions) and is over 60 years old.
NCT00000378 Antidepressant Treatment of Melancholia in Late Life Completed New York State Psychiatric Institute Phase 4 1997-07-01 The purpose of this study is to compare the safety and effectiveness of a select serotonin re-uptake inhibitor (SSRI, sertraline) and a tricyclic antidepressant (TCA, nortriptyline) in outpatients over the age of 60 who have major depression. SSRIs are effective in the treatment of major depression. However, there is also evidence that SSRIs may be significantly less effective than TCAs for patients with late-life major depression with melancholia. Since SSRIs seem to be easier to take than TCAs and are more widely prescribed, it is important to determine which of these types of antidepressants works best to treat these patients. Patients will be assigned randomly to receive either sertraline (a SSRI) or nortriptyline (a TCA) for 12 weeks. Patients will be monitored for symptoms, side effects, and quality of life. If a patient responds to treatment, he/she will participate in a 6-month continuation phase in which he/she will continue to receive the same medication. An individual may be eligible for this study if he/she: Has unipolar major depression (with some exceptions) and is over 60 years old.
NCT00000384 Treatment of Obsessive-Compulsive Disorder (OCD) in Children Completed National Institute of Mental Health (NIMH) Phase 3 1997-05-01 The purpose of this study is to compare 3 treatments for children with OCD: medication (sertraline, SER) alone vs OCD-specific therapy (Cognitive Behavior Therapy, CBT) vs medication plus therapy. Some patients will receive an inactive placebo (PBO) instead of medication and/or Educational Support (ES, non-psychological treatment) instead of therapy. One in 200 children suffer from OCD, but few receive appropriate treatment. Both CBT and medication seem to be effective, but their effectiveness, alone and in combination, has not been evaluated. There are 2 phases to this trial. In Phase I the child will receive 1 of the following 6 treatments for 12 weeks: 1) SER alone; 2) pill PBO alone; 3) CBT alone; 4) SER plus CBT; 5) SER plus ES; 6) pill PBO plus ES. If the child responds to treatment, he/she will go on to Phase II in which the treatment will be slowly reduced, then stopped (discontinued), over time to test the treatment's durability. The child will be evaluated at Weeks 1, 4, 8, 12 (Phase I treatment), and Weeks 16, 20, 24, and 28 (Phase II discontinuation) to see how effective and durable the treatment is in treating your child's OCD. A child may be eligible for this study if he/she: Has obsessive-compulsive disorder (OCD) and is 8 - 16 years old.
NCT00000384 Treatment of Obsessive-Compulsive Disorder (OCD) in Children Completed University of Pennsylvania Phase 3 1997-05-01 The purpose of this study is to compare 3 treatments for children with OCD: medication (sertraline, SER) alone vs OCD-specific therapy (Cognitive Behavior Therapy, CBT) vs medication plus therapy. Some patients will receive an inactive placebo (PBO) instead of medication and/or Educational Support (ES, non-psychological treatment) instead of therapy. One in 200 children suffer from OCD, but few receive appropriate treatment. Both CBT and medication seem to be effective, but their effectiveness, alone and in combination, has not been evaluated. There are 2 phases to this trial. In Phase I the child will receive 1 of the following 6 treatments for 12 weeks: 1) SER alone; 2) pill PBO alone; 3) CBT alone; 4) SER plus CBT; 5) SER plus ES; 6) pill PBO plus ES. If the child responds to treatment, he/she will go on to Phase II in which the treatment will be slowly reduced, then stopped (discontinued), over time to test the treatment's durability. The child will be evaluated at Weeks 1, 4, 8, 12 (Phase I treatment), and Weeks 16, 20, 24, and 28 (Phase II discontinuation) to see how effective and durable the treatment is in treating your child's OCD. A child may be eligible for this study if he/she: Has obsessive-compulsive disorder (OCD) and is 8 - 16 years old.
NCT00000440 Sertraline and Naltrexone for Alcohol Dependence Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 1969-12-31 This study is a double-blind, placebo-controlled outpatient trial to improve, through the addition of sertraline (Zoloft), the abstinence and relapse rates in alcohol- dependent individuals currently taking naltrexone (Revia).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Sertraline Hydrochloride

Condition Name

Condition Name for Sertraline Hydrochloride
Intervention Trials
Depression 70
Major Depressive Disorder 35
Healthy 17
Post-Traumatic Stress Disorder 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Sertraline Hydrochloride
Intervention Trials
Depression 138
Depressive Disorder 123
Depressive Disorder, Major 66
Disease 60
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Sertraline Hydrochloride

Trials by Country

Trials by Country for Sertraline Hydrochloride
Location Trials
United States 422
Canada 31
Japan 20
Brazil 15
Australia 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Sertraline Hydrochloride
Location Trials
New York 42
Pennsylvania 31
California 31
Texas 26
Massachusetts 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Sertraline Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Sertraline Hydrochloride
Clinical Trial Phase Trials
Phase 4 102
Phase 3 52
Phase 2/Phase 3 11
[disabled in preview] 82
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Sertraline Hydrochloride
Clinical Trial Phase Trials
Completed 171
Recruiting 42
Terminated 26
[disabled in preview] 57
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Sertraline Hydrochloride

Sponsor Name

Sponsor Name for Sertraline Hydrochloride
Sponsor Trials
National Institute of Mental Health (NIMH) 49
Pfizer 29
Duke University 13
[disabled in preview] 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Sertraline Hydrochloride
Sponsor Trials
Other 357
Industry 92
NIH 84
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Colorcon
McKinsey
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.